{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:20:13Z","timestamp":1792621213717,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004410","name":"TUBITAK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-024-07413-w","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:25:02Z","timestamp":1738668302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of selective SWI\/SNF dependencies in enzalutamide-resistant prostate cancer"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-6078","authenticated-orcid":false,"given":"Bengul","family":"Gokbayrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut Berkay","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Lingadahalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunc","family":"Morova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-3139","authenticated-orcid":false,"given":"Chia-Chi Flora","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Ersoy Fazlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pak Lok Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-0968","authenticated-orcid":false,"given":"Batuhan M.","family":"Kalkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-7748","authenticated-orcid":false,"given":"Paloma","family":"Cejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-8939","authenticated-orcid":false,"given":"Sonia H. Y.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-5082","authenticated-orcid":false,"given":"Akane","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceyda","family":"Acilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-9158","authenticated-orcid":false,"given":"Tamer T.","family":"Onder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-2613","authenticated-orcid":false,"given":"Tugba","family":"Bagci-Onder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8260-5355","authenticated-orcid":false,"given":"James T.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-5844","authenticated-orcid":false,"given":"Nathan A.","family":"Lack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"7413_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"7413_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408\u20131418 (2018).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380, 1235\u20131246 (2019).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.eururo.2016.07.027","volume":"71","author":"A Heidenreich","year":"2017","unstructured":"Heidenreich, A. et al. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Eur. Urol. 71, 534\u2013542 (2017).","journal-title":"Eur. Urol."},{"key":"7413_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424\u2013433 (2014).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465\u20132474 (2018).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1470-2045(18)30898-2","volume":"20","author":"B Tombal","year":"2019","unstructured":"Tombal, B. et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 556\u2013569 (2019).","journal-title":"Lancet Oncol."},{"key":"7413_CR9","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg, C. N. et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 382, 2197\u20132206 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR10","first-page":"2974","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Orthod. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Orthod."},{"key":"7413_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero, C. et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat. Rev. 41, 884\u2013892 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"7413_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41388-020-01598-0","volume":"40","author":"N Formaggio","year":"2021","unstructured":"Formaggio, N., Rubin, M. A. & Theurillat, J.-P. Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene 40, 1205\u20131216 (2021).","journal-title":"Oncogene"},{"key":"7413_CR13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","volume":"2","author":"AW Wyatt","year":"2016","unstructured":"Wyatt, A. W. et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2, 1598\u20131606 (2016).","journal-title":"JAMA Oncol."},{"key":"7413_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"key":"7413_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309\u20131322 (2013).","journal-title":"Cell"},{"key":"7413_CR16","doi-asserted-by":"crossref","unstructured":"Kukkonen, K. et al. Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response. Cancers 13, (2021).","DOI":"10.3390\/cancers13133325"},{"key":"7413_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fonc.2018.00180","volume":"8","author":"A Vander Ark","year":"2018","unstructured":"Vander Ark, A., Cao, J. & Li, X. Mechanisms and approaches for overcoming enzalutamide resistance in prostate cancer. Front. Oncol. 8, 180 (2018).","journal-title":"Front. Oncol."},{"key":"7413_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s40610-017-0079-1","volume":"3","author":"Z Culig","year":"2017","unstructured":"Culig, Z. Molecular mechanisms of enzalutamide resistance in prostate cancer. Curr. Mol. Biol. Rep. 3, 230\u2013235 (2017).","journal-title":"Curr. Mol. Biol. Rep."},{"key":"7413_CR19","doi-asserted-by":"publisher","first-page":"111084","DOI":"10.18632\/oncotarget.22560","volume":"8","author":"CJ King","year":"2017","unstructured":"King, C. J. et al. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget 8, 111084\u2013111095 (2017).","journal-title":"Oncotarget"},{"key":"7413_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19328-1","volume":"11","author":"J Cyrta","year":"2020","unstructured":"Cyrta, J. et al. Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity. Nat. Commun. 11, 5549 (2020).","journal-title":"Nat. Commun."},{"key":"7413_CR21","doi-asserted-by":"publisher","first-page":"169ra10","DOI":"10.1126\/scitranslmed.3005211","volume":"5","author":"MJ Aryee","year":"2013","unstructured":"Aryee, M. J. et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 169ra10 (2013).","journal-title":"Sci. Transl. Med."},{"key":"7413_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","volume":"8","author":"D Brocks","year":"2014","unstructured":"Brocks, D. et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 8, 798\u2013806 (2014).","journal-title":"Cell Rep."},{"key":"7413_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85812-3","volume":"11","author":"MR Peter","year":"2021","unstructured":"Peter, M. R. et al. Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer. Sci. Rep. 11, 6630 (2021).","journal-title":"Sci. Rep."},{"key":"7413_CR24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao, S. G. et al. The DNA methylation landscape of advanced prostate cancer. Nat. Genet. 52, 778\u2013789 (2020).","journal-title":"Nat. Genet."},{"key":"7413_CR25","doi-asserted-by":"publisher","unstructured":"Shetty, A. et al. Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms. bioRxiv 2021.06.02.446619 https:\/\/doi.org\/10.1101\/2021.06.02.446619 (2021).","DOI":"10.1101\/2021.06.02.446619"},{"key":"7413_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22139-7","volume":"12","author":"SC Baca","year":"2021","unstructured":"Baca, S. C. et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat. Commun. 12, 1979 (2021).","journal-title":"Nat. Commun."},{"key":"7413_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84\u201388 (2017).","journal-title":"Science"},{"key":"7413_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"7413_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies, A. H., Beltran, H. & Zoubeidi, A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271\u2013286 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"7413_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436\u2013439 (2005).","journal-title":"Nature"},{"key":"7413_CR31","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.celrep.2014.11.008","volume":"9","author":"C Cai","year":"2014","unstructured":"Cai, C. et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 9, 1618\u20131627 (2014).","journal-title":"Cell Rep."},{"key":"7413_CR32","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim, J. et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 25, 2808\u20132820.e4 (2018).","journal-title":"Cell Rep."},{"key":"7413_CR33","doi-asserted-by":"publisher","first-page":"9911","DOI":"10.1074\/jbc.RA119.008152","volume":"294","author":"Y Bai","year":"2019","unstructured":"Bai, Y. et al. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. J. Biol. Chem. 294, 9911\u20139923 (2019).","journal-title":"J. Biol. Chem."},{"key":"7413_CR34","doi-asserted-by":"publisher","first-page":"E4179","DOI":"10.1073\/pnas.1719168115","volume":"115","author":"A Sehrawat","year":"2018","unstructured":"Sehrawat, A. et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc. Natl. Acad. Sci. USA 115, E4179\u2013E4188 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7413_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21860-7","volume":"12","author":"Y He","year":"2021","unstructured":"He, Y. et al. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat. Commun. 12, 1521 (2021).","journal-title":"Nat. Commun."},{"key":"7413_CR36","first-page":"TPS335","volume":"37","author":"M-E Taplin","year":"2019","unstructured":"Taplin, M.-E. et al. ProSTAR: A phase Ib\/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Orthod. 37, TPS335\u2013TPS335 (2019).","journal-title":"J. Clin. Orthod."},{"key":"7413_CR37","unstructured":"ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480646."},{"key":"7413_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05146-4","volume":"13","author":"O Yedier-Bayram","year":"2022","unstructured":"Yedier-Bayram, O. et al. EPIKOL, a chromatin-focused CRISPR\/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities. Cell Death Dis. 13, 1\u201311 (2022).","journal-title":"Cell Death Dis."},{"key":"7413_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"7413_CR40","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nm.3830","volume":"21","author":"R Malik","year":"2015","unstructured":"Malik, R. et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat. Med. 21, 344\u2013352 (2015).","journal-title":"Nat. Med."},{"key":"7413_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278\u2013282 (2014).","journal-title":"Nature"},{"key":"7413_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop, J. L. et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54\u201371 (2017).","journal-title":"Cancer Discov."},{"key":"7413_CR43","unstructured":"DepMap: The Cancer Dependency Map Project at Broad Institute. https:\/\/depmap.org\/portal\/."},{"key":"7413_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbrc.2018.09.149","volume":"505","author":"ML Jin","year":"2018","unstructured":"Jin, M. L., Kim, Y. W. & Jeong, K. W. BAF53A regulates androgen receptor-mediated gene expression and proliferation in LNCaP cells. Biochem. Biophys. Res. Commun. 505, 618\u2013623 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"7413_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17460441.2020.1821644","volume":"16","author":"A Hartley","year":"2021","unstructured":"Hartley, A., Leung, H. Y. & Ahmad, I. Targeting the BAF complex in advanced prostate cancer. Expert Opin. Drug Discov. 16, 173\u2013181 (2021).","journal-title":"Expert Opin. Drug Discov."},{"key":"7413_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01023-7","volume":"13","author":"KA Giles","year":"2021","unstructured":"Giles, K. A. et al. BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer. Clin. Epigenetics 13, 37 (2021).","journal-title":"Clin. Epigenetics"},{"key":"7413_CR47","doi-asserted-by":"publisher","unstructured":"Muthuswami, R. et al. BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer. J. Cell. Physiol. https:\/\/doi.org\/10.1002\/jcp.28161 (2019).","DOI":"10.1002\/jcp.28161"},{"key":"7413_CR48","doi-asserted-by":"publisher","first-page":"30605","DOI":"10.1074\/jbc.M304582200","volume":"278","author":"TW Marshall","year":"2003","unstructured":"Marshall, T. W., Link, K. A., Petre-Draviam, C. E. & Knudsen, K. E. Differential requirement of SWI\/SNF for androgen receptor activity. J. Biol. Chem. 278, 30605\u201330613 (2003).","journal-title":"J. Biol. Chem."},{"key":"7413_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1172\/JCI123557","volume":"129","author":"Y Ding","year":"2019","unstructured":"Ding, Y. et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J. Clin. Invest. 129, 759\u2013773 (2019).","journal-title":"J. Clin. Invest."},{"key":"7413_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molcel.2018.06.040","volume":"71","author":"GJ Sandoval","year":"2018","unstructured":"Sandoval, G. J. et al. Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. Mol. Cell 71, 554\u2013566.e7 (2018).","journal-title":"Mol. Cell"},{"key":"7413_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fnmol.2017.00243","volume":"10","author":"G Sokpor","year":"2017","unstructured":"Sokpor, G., Xie, Y., Rosenbusch, J. & Tuoc, T. Chromatin remodeling BAF (SWI\/SNF) complexes in neural development and disorders. Front. Mol. Neurosci. 10, 243 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"7413_CR52","doi-asserted-by":"crossref","unstructured":"Hota, S. K. et al. Dynamic BAF chromatin remodeling complex subunit inclusion promotes temporally distinct gene expression programs in cardiogenesis. Development 146, (2019).","DOI":"10.1242\/dev.174086"},{"key":"7413_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41576-020-0278-0","volume":"22","author":"BK Cenik","year":"2021","unstructured":"Cenik, B. K. & Shilatifard, A. COMPASS and SWI\/SNF complexes in development and disease. Nat. Rev. Genet. 22, 38\u201358 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"7413_CR54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature08911","volume":"463","author":"L Ho","year":"2010","unstructured":"Ho, L. & Crabtree, G. R. Chromatin remodelling during development. Nature 463, 474\u2013484 (2010).","journal-title":"Nature"},{"key":"7413_CR55","doi-asserted-by":"crossref","unstructured":"Tsherniak, A. et al. Defining a Cancer Dependency Map. Cell 170, 564\u2013576 (2017).","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"7413_CR56","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","volume":"175","author":"N Mashtalir","year":"2018","unstructured":"Mashtalir, N. et al. Modular Organization and Assembly of SWI\/SNF Family Chromatin Remodeling Complexes. Cell 175, 1272\u20131288.e20 (2018).","journal-title":"Cell"},{"key":"7413_CR57","doi-asserted-by":"publisher","first-page":"10155","DOI":"10.1021\/acs.jmedchem.8b01318","volume":"61","author":"JPN Papillon","year":"2018","unstructured":"Papillon, J. P. N. et al. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)\/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)\/SMARCA4-Mutant Cancers. J. Med. Chem. 61, 10155\u201310172 (2018).","journal-title":"J. Med. Chem."},{"key":"7413_CR58","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","volume":"15","author":"W Farnaby","year":"2019","unstructured":"Farnaby, W. et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15, 672\u2013680 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"7413_CR59","doi-asserted-by":"publisher","unstructured":"Xiao, L. et al. Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer. Nature https:\/\/doi.org\/10.1038\/s41586-021-04246-z (2021).","DOI":"10.1038\/s41586-021-04246-z"},{"key":"7413_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nmeth.4556","volume":"15","author":"RM Layer","year":"2018","unstructured":"Layer, R. M. et al. GIGGLE: a search engine for large-scale integrated genome analysis. Nat. Methods 15, 123\u2013126 (2018).","journal-title":"Nat. Methods"},{"key":"7413_CR61","doi-asserted-by":"publisher","first-page":"eaav1898","DOI":"10.1126\/science.aav1898","volume":"362","author":"MR Corces","year":"2018","unstructured":"Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, eaav1898 (2018).","journal-title":"Science"},{"key":"7413_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26042-z","volume":"12","author":"P Cejas","year":"2021","unstructured":"Cejas, P. et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat. Commun. 12, 5775 (2021).","journal-title":"Nat. Commun."},{"key":"7413_CR63","doi-asserted-by":"publisher","unstructured":"Uusi-M\u00e4kel\u00e4, J. et al. Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression. bioRxiv 2020.09.08.287268 https:\/\/doi.org\/10.1101\/2020.09.08.287268 (2020).","DOI":"10.1101\/2020.09.08.287268"},{"key":"7413_CR64","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","volume":"19","author":"A Urbanucci","year":"2017","unstructured":"Urbanucci, A. et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 19, 2045\u20132059 (2017).","journal-title":"Cell Rep."},{"key":"7413_CR65","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.1630","volume":"28","author":"CY McLean","year":"2010","unstructured":"McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495\u2013501 (2010).","journal-title":"Nat. Biotechnol."},{"key":"7413_CR66","doi-asserted-by":"publisher","first-page":"40690","DOI":"10.18632\/oncotarget.9816","volume":"7","author":"DJ Coleman","year":"2016","unstructured":"Coleman, D. J. et al. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7, 40690\u201340703 (2016).","journal-title":"Oncotarget"},{"key":"7413_CR67","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8, 444\u2013457 (2018).","journal-title":"Cancer Discov."},{"key":"7413_CR68","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1124\/mol.62.5.1027","volume":"62","author":"M Maggiolini","year":"2002","unstructured":"Maggiolini, M. et al. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol. Pharmacol. 62, 1027\u20131035 (2002).","journal-title":"Mol. Pharmacol."},{"key":"7413_CR69","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","volume":"15","author":"S Prekovic","year":"2016","unstructured":"Prekovic, S. et al. The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol. Cancer Ther. 15, 1702\u20131712 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"7413_CR70","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research Network.","year":"2015","unstructured":"Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"7413_CR71","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-019-0477-9","volume":"51","author":"S Schick","year":"2019","unstructured":"Schick, S. et al. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nat. Genet. 51, 1399\u20131410 (2019).","journal-title":"Nat. Genet."},{"key":"7413_CR72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","volume":"26","author":"KC Helming","year":"2014","unstructured":"Helming, K. C., Wang, X. & Roberts, C. W. M. Vulnerabilities of Mutant SWI\/SNF Complexes in Cancer. Cancer Cell 26, 309\u2013317 (2014).","journal-title":"Cancer Cell"},{"key":"7413_CR73","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","volume":"40","author":"M Wanior","year":"2021","unstructured":"Wanior, M., Kr\u00e4mer, A., Knapp, S. & Joerger, A. C. Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy. Oncogene 40, 3637\u20133654 (2021).","journal-title":"Oncogene"},{"key":"7413_CR74","doi-asserted-by":"publisher","unstructured":"Martin, B. J. E. et al. Global identification of SWI\/SNF targets reveals compensation by EP400. Cell https:\/\/doi.org\/10.1016\/j.cell.2023.10.006 (2023).","DOI":"10.1016\/j.cell.2023.10.006"},{"key":"7413_CR75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-019-1115-5","volume":"569","author":"D Barisic","year":"2019","unstructured":"Barisic, D., Stadler, M. B., Iurlaro, M. & Sch\u00fcbeler, D. Mammalian ISWI and SWI\/SNF selectively mediate binding of distinct transcription factors. Nature 569, 136\u2013140 (2019).","journal-title":"Nature"},{"key":"7413_CR76","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/onc.2017.330","volume":"37","author":"S Stelloo","year":"2018","unstructured":"Stelloo, S. et al. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. Oncogene 37, 313\u2013322 (2018).","journal-title":"Oncogene"},{"key":"7413_CR77","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/s41388-021-01887-2","volume":"40","author":"K-M Launonen","year":"2021","unstructured":"Launonen, K.-M. et al. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. Oncogene 40, 4567\u20134579 (2021).","journal-title":"Oncogene"},{"key":"7413_CR78","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/0008-5472.CAN-07-6392","volume":"68","author":"KA Link","year":"2008","unstructured":"Link, K. A. et al. Targeting the BAF57 SWI\/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res. 68, 4551\u20134558 (2008).","journal-title":"Cancer Res."},{"key":"7413_CR79","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.chembiol.2020.10.001","volume":"28","author":"A Richters","year":"2021","unstructured":"Richters, A. et al. Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 Inhibitors. Cell Chem. Biol. 28, 134\u2013147.e14 (2021).","journal-title":"Cell Chem. Biol."},{"key":"7413_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"7413_CR81","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"7413_CR82","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"7413_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"7413_CR84","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"7413_CR85","doi-asserted-by":"publisher","first-page":"D658","DOI":"10.1093\/nar\/gkw983","volume":"45","author":"S Mei","year":"2017","unstructured":"Mei, S. et al. Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 45, D658\u2013D662 (2017).","journal-title":"Nucleic Acids Res."},{"key":"7413_CR86","doi-asserted-by":"publisher","first-page":"D729","DOI":"10.1093\/nar\/gky1094","volume":"47","author":"R Zheng","year":"2019","unstructured":"Zheng, R. et al. Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 47, D729\u2013D735 (2019).","journal-title":"Nucleic Acids Res."},{"key":"7413_CR87","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"7413_CR88","doi-asserted-by":"publisher","first-page":"W39","DOI":"10.1093\/nar\/gkv416","volume":"43","author":"TL Bailey","year":"2015","unstructured":"Bailey, T. L., Johnson, J., Grant, C. E. & Noble, W. S. The MEME suite. Nucleic Acids Res. 43, W39\u2013W49 (2015).","journal-title":"Nucleic Acids Res."},{"key":"7413_CR89","doi-asserted-by":"crossref","unstructured":"Gu, Z. & H\u00fcbschmann, D. rGREAT: an R\/bioconductor package for functional enrichment on genomic regions. Bioinformatics 39, (2023).","DOI":"10.1093\/bioinformatics\/btac745"},{"key":"7413_CR90","doi-asserted-by":"publisher","first-page":"17087","DOI":"10.1073\/pnas.1108745108","volume":"108","author":"A Kumar","year":"2011","unstructured":"Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087\u201317092 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7413_CR91","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"7413_CR92","unstructured":"Van Der Auwera, G. O. & Connor, B. D. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra. (O\u2019Reilly Media, 2020)."},{"key":"7413_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"7413_CR94","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies, A. et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat. Cell Biol. 23, 1023\u20131034 (2021).","journal-title":"Nat. Cell Biol."},{"key":"7413_CR95","doi-asserted-by":"publisher","first-page":"108416","DOI":"10.1016\/j.celrep.2020.108416","volume":"33","author":"DL Christian","year":"2020","unstructured":"Christian, D. L. et al. DNMT3A haploinsufficiency results in behavioral deficits and global epigenomic dysregulation shared across neurodevelopmental disorders. Cell Rep. 33, 108416 (2020).","journal-title":"Cell Rep."},{"key":"7413_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"7413_CR97","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07413-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:25:09Z","timestamp":1738668309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07413-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7413"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-07413-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"James T. Lynch is an AstraZeneca stock holder and a former scientist in AstraZeneca with current employer Amphista Therapeutics (Amphista Therapeutics Ltd, Suite 4 (First Floor), Cori Building, Granta Park, Great Abington, Cambridge, CB21 6GQ).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}